Allogeneic Cord Blood for Neurological Diseases in Adults

The Medical Pavilion Bahamas

Status and phase: Withdrawn; Early Phase 1

Conditions: Spinal Cord Injuries; Stroke; Neurological Diseases

Treatments: Biological: Allogeneic cord blood treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT05515419

101

Details and patient eligibility

About

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood therapy for adult patients with neurological diseases.

Full description

Neurological diseases such as stroke or spinal cord injuries are very common etiologies causing disability in developed countries. Cord blood possess various stem and progenitor cells, as well as their secreted regenerative factors, and is known to repair injured brain. The investigators clinical research aims to determine the safety and efficacy of allogeneic Umbilical Cord Blood for adult patients with neurological diseases such as stroke and spinal cord injury.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ischemic or hemorrhagic stroke (onset < 24 months), or
• Spinal cord injury (onset < 24 months)

Exclusion criteria

• Raised intracranial pressure
• Malignant cancer
• Renal failure
• Severe pulmonary dysfunction

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Allogeneic cord blood therapy

Experimental group

Description:

Allogeneic cord blood therapy

Treatment:

Biological: Allogeneic cord blood treatment